The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pain analysis from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) with bone metastases.
Sten Nilsson
Consultant or Advisory Role - Algeta
A. Oliver Sartor
Consultant or Advisory Role - Algeta; Bayer
Oyvind S. Bruland
Consultant or Advisory Role - Algeta
Stock Ownership - Algeta
Honoraria - Algeta
Fang Fang
Employment or Leadership Position - Bayer
Stock Ownership - Bayer
Paul Cislo
Employment or Leadership Position - Bayer
Stock Ownership - Bayer
Anne-Kirsti Aksnes
Employment or Leadership Position - Algeta
Stock Ownership - Algeta
Chris Parker
Consultant or Advisory Role - Algeta (U); Bayer